Tag: Astellas
Winding-Down of Research Operations but Astellas Retains Promising Antibody-Drug Conjugate R&D...
In a surprise move to most, but expected by industry insiders, Astellas Pharma, a Japan-based company focusing on the development of novel treatments in Urology,...
Phase I Data of Enfortumab Vedotin in Metastatic Urothelial Cancer Supports...
Updated phase I data for enfortumab vedotin, also known as ASG-22ME or ASG-22CE , studied as monotherapy treatment for metastatic urothelial cancer (mUC) were...
Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...
Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E, presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...
Astellas Presents Study-results of two Investigational ADCs in Patients with Metastatic...
With two approved antibody-drug conjugates and a large number of ADCs in clinical development scientists have made significant advances bringing novel ADC technology to the forefront...
